Complete, Durable Remission of Advanced Hepatocellular Carcinoma under Treatment with Viscum album Extracts: A Case Report.

Autor:	Orange M; Oncological Day Clinic, Klinik Arlesheim, Arlesheim, Switzerland., Poidimani N; Day Clinic Integrative Oncology, Casa Andrea Cristoforo, Ascona, Switzerland.; Centre Integrative Medicine, Kantonspital, St. Gallen, Switzerland.; Department of Gastroenterology, Ospedale San Paolo, Milano, Italy., Crosignani A; Department of Gastroenterology, Ospedale San Paolo, Milano, Italy., Werthmann PG; Center for Complementary Medicine, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Institute for Applied Epistemology and Medical Methodology at the University of Witten/Herdecke, Freiburg, Germany.; Department of General and Visceral Surgery, University Hospital Ulm, Ulm, Germany., Bertotto C; Day Clinic Integrative Oncology, Casa Andrea Cristoforo, Ascona, Switzerland.; Centre Integrative Medicine, Kantonspital, St. Gallen, Switzerland.
Jazyk:	angličtina
Zdroj:	Complementary medicine research [Complement Med Res] 2022; Vol. 29 (6), pp. 483-491. Date of Electronic Publication: 2022 Jun 28.
DOI:	10.1159/000525409
Abstrakt:	Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths. Early-stage disease is treated with curative intent, but most patients present with advanced HCC, which carries a poor prognosis. Viscum album extracts (VAE) are used by cancer patients as an adjunct treatment or palliation. Case Presentation: A 51-year-old female presented with relapsing multifocal HCC. She declined palliative treatment and commenced intravenous VAE treatment in conjunction with intravenous hepato-protective L-ornithine-L-aspartate (LOLA). She experienced a significant improvement of life-quality and performance status. After 3 months, a significant regression was noted on computerized tomography, and α-fetoprotein was in normal range. Imaging 11 months later confirmed a complete regression. The VAE and LOLA treatment continues to date. The patient had no other cancer-directed therapy. The regression is sustained for more than 5 years at publication, confirmed by regular imaging and serology. The patient is experiencing an unrestricted quality of life. Conclusion: Complete regression of advanced HCC is rare. Responses of HCC to VAE treatment have been reported before. However, this is the first documented case with a complete and durable regression of an HCC under treatment with VAE. Further studies should evaluate VAE treatment in HCC, especially when administered in forms as reported here. (© 2022 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu